OBJECTIVE: Given that the @entity1 's Health Initiative reported in 2002 increased risks of @entity0 and @entity65 with @entity34 ( @entity34 ) use and many @entity1 discontinued use, we assessed the use and perceived efficacy of complementary and alternative medicines (CAMs) for menopausal symptom relief after discontinuation of @entity34 . METHODS: Postmenopausal @entity1 aged 50 to 65 years within the United Kingdom Collaborative Trial of @entity43 Screening who were willing to take part in a secondary study were mailed a survey to evaluate menopausal symptom management. Use and perceived efficacy of CAMs for relief of @entity1109 ( @entity1109 ) upon discontinuation of @entity34 were examined. RESULTS: The survey was sent to 15,000 @entity1 between July 2 and July 9, 2008. Seventy-one percent (10,662 of 15,000) responded, and 10,607 @entity1 with complete data were included. Ever use of @entity34 was reported by 60.2% (6,383 of 10,607). At survey completion, 79.3% (5,060 of 6,383) had discontinued @entity34 , with 89.7% (4,540 of 5,060) of the latter reporting using one or more CAMs for @entity1109 relief. About 70.4% (3,561 of 5,060) used herbal remedies, with evening primrose oil (48.6%; 2,205 of 4,540) and black cohosh (30.3%;1,377 of 4,540) being most commonly used. Exercise was used by 68.2% (3,098 of 4,540), whereas other behavioral/lifestyle approaches were less frequently reported (13.9%; 629 of 4,540). Contrarily, more @entity1 (57%-72%) rated behavioral/lifestyle approaches as effective compared with herbal remedies (28%-46%; rating >= 4 on a "helpfulness" scale from 1-10). Among medical treatments, selective @entity750 reuptake inhibitors were used by 10% and rated effective by 72.1%. CONCLUSIONS: Although more @entity1 use over-the-counter medicines, behavioral/lifestyle approaches seem to provide better relief of @entity1109 . There is a pressing need for better evidence-based lay information to support decision-making on CAM use for relief of @entity1109 .

Use and perceived efficacy of complementary and alternative medicines after discontinuation of @entity34 : a nested United Kingdom Collaborative Trial of XXXX Screening cohort study.

@entity1 :: ('9606', 'Species') :: ['women', 'Women'] @entity43 :: ('MESH:D010051', 'Disease') :: ['Ovarian Cancer'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1109 :: ('MESH:D012678', 'Disease') :: ['VMS', 'vasomotor symptoms'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular events'] @entity34 :: ('MESH:D016609', 'Disease') :: ['hormone therapy', 'HT']
@entity43 :: (MESH:D010051,Disease) :: ['Ovarian Cancer']
